TIL Key Statistics, Chart & Performance
The current stock price of TIL is 11.48 USD. In the past month the price decreased by -38.71%. In the past year, price decreased by -57.34%.
TIL Latest News, Press Relases and Analysis
TIL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.49B | ||
| AMGN | AMGEN INC | 15.6 | 183.64B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.76 | 110.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.75 | 56.34B | ||
| INSM | INSMED INC | N/A | 44.18B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.87 | 26.68B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 21.97B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About TIL
Company Profile
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
Company Info
INSTIL BIO INC
3963 Maple Avenue, Suite 350
Dallas TEXAS 75219 US
CEO: Bronson Crouch
Employees: 14
Phone: 19724993350
INSTIL BIO INC / TIL FAQ
What does INSTIL BIO INC do?
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
What is the stock price of INSTIL BIO INC today?
The current stock price of TIL is 11.48 USD. The price decreased by -2.96% in the last trading session.
What is the dividend status of INSTIL BIO INC?
TIL does not pay a dividend.
How is the ChartMill rating for INSTIL BIO INC?
TIL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does INSTIL BIO INC have?
INSTIL BIO INC (TIL) currently has 14 employees.
What is the market capitalization of TIL stock?
INSTIL BIO INC (TIL) has a market capitalization of 77.49M USD. This makes TIL a Micro Cap stock.
What is the Short Interest ratio of INSTIL BIO INC (TIL) stock?
The outstanding short interest for INSTIL BIO INC (TIL) is 10.93% of its float.
TIL Technical Analysis
TIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TIL. While TIL seems to be doing ok healthwise, there are quite some concerns on its profitability.
TIL Financial Highlights
Over the last trailing twelve months TIL reported a non-GAAP Earnings per Share(EPS) of -11.39. The EPS increased by 1.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.59% | ||
| ROE | -64.18% | ||
| Debt/Equity | 0.64 |
TIL Forecast & Estimates
8 analysts have analysed TIL and the average price target is 97.67 USD. This implies a price increase of 750.74% is expected in the next year compared to the current price of 11.48.